Amgen Inc. closed $68.59 short of its 52-week high ($346.85), which the company reached on July 25th.

AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), Eaton Corp. plc ...

Amgen, one of several biotechnology companies that have been expanding operations in Holly Springs, is poised to announce ...

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...

While most of this collection of Dow Industrials is too pricey and reveals only skinny dividends, one of the ten lowest ...

State and local officials are poised to announce a major economic development deal -- one that could bring hundreds of jobs to Holly Springs, people familiar with the deal told WRAL News.

One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...

The donation to Rush’s orthopedic department, the largest ever, creates four new endowed positions and programs.

The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.

The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...

Eli Lilly & Co. Inc.'s stock (LLY) rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk's Wegovy in a head-to-head study.